Literature DB >> 17458569

Reversion of resistance in relapsing infection caused by a glycopeptide-intermediate methicillin-resistant Staphylococcus aureus isolate.

T-D Huang1, C Almpanis, O Denis, C Nonhoff, B Delaere, Y Glupczynski.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17458569     DOI： 10.1007/s10096-007-0297-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  10 in total

1.  Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.

Authors:  S Boyle-Vavra; S K Berke; J C Lee; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management.

Authors:  Dag Harmsen; Heike Claus; Wolfgang Witte; Jörg Rothgänger; Hermann Claus; Doris Turnwald; Ulrich Vogel
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

3.  Vancomycin-resistant Staphylococcus aureus: no apocalypse now.

Authors:  F W Goldstein; M D Kitzis
Journal:  Clin Microbiol Infect       Date:  2003-08       Impact factor: 8.067

4.  Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals.

Authors:  C Nonhoff; O Denis; M J Struelens
Journal:  Clin Microbiol Infect       Date:  2005-03       Impact factor: 8.067

5.  In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals.

Authors:  Olivier Denis; Ariane Deplano; Claire Nonhoff; Marie Hallin; Raf De Ryck; Raymond Vanhoof; Ricardo De Mendonça; Marc J Struelens
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 6.  Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus.

Authors:  C Ruef
Journal:  Infection       Date:  2004-12       Impact factor: 3.553

7.  Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy.

Authors:  K Sieradzki; T Leski; J Dick; L Borio; A Tomasz
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

8.  Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.

Authors:  T R Walsh; A Bolmström; A Qwärnström; P Ho; M Wootton; R A Howe; A P MacGowan; D Diekema
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

9.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

Authors:  Scott K Fridkin; Jeff Hageman; Linda K McDougal; Jasmine Mohammed; William R Jarvis; Trish M Perl; Fred C Tenover
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079
  10 in total
  2 in total

1.  A novel sequence-based coa genotyping method to discriminate nosocomial methicillin-resistant Staphylococcus aureus isolates.

Authors:  Q T Li; Y Z Zhu; K Dong; C Liu; Y H Zhou; Y X Ni; X K Guo
Journal:  Ir J Med Sci       Date:  2011-01-29       Impact factor: 1.568

2.  Compensation of fitness costs and reversibility of antibiotic resistance mutations.

Authors:  Pia Schulz zur Wiesch; Jan Engelstädter; Sebastian Bonhoeffer
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.